Shaw, Pamela J.
Pamela Shaw
VIAF ID: 12628669 (Personal)
Permalink: http://viaf.org/viaf/12628669
Preferred Forms
- 100 0 _ ‡a Pamela Shaw
- 200 _ | ‡a Shaw ‡b Pamela J.
-
-
- 100 1 _ ‡a Shaw, Pamela J.
-
-
- 100 1 _ ‡a Shaw, Pamela J.
-
- 100 1 _ ‡a Shaw, Pamela J.
- 100 1 _ ‡a Shaw, Pamela J.
4xx's: Alternate Name Forms (8)
Works
Title | Sources |
---|---|
Motor neuron disorders and related diseases | |
Neurology, 2018: | |
Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. | |
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. | |
Pattern of spread and prognosis in lower limb-onset ALS. | |
Physical activity as an exogenous risk factor in motor neuron disease (MND): a review of the evidence | |
Poly(ADP-ribose) polymerase is found in both the nucleus and cytoplasm of human CNS neurons. | |
Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer-type pathology in the ageing brain. | |
Preface | |
Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. | |
Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis | |
The Project MinE databrowser: bringing large-scale whole-genome sequencing in ALS to researchers and the public | |
Protocol for diaphragm pacing in patients with respiratory muscle weakness due to motor neurone disease (DiPALS): a randomised controlled trial. | |
The quantitative autoradiographic distribution of [3H]MK-801 binding sites in the normal human spinal cord | |
Rasch analysis of the hospital anxiety and depression scale (HADS) for use in motor neurone disease | |
Reconsidering the causality of TIA1 mutations in ALS. | |
Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeat | |
Respiratory management of motor neurone disease: a review of current practice and new developments | |
Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. | |
The role of cranial and thoracic electromyography within diagnostic criteria for amyotrophic lateral sclerosis | |
The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease | |
S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis | |
Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies) | |
Selective loss of neurofilament expression in Cu/Zn superoxide dismutase (SOD1) linked amyotrophic lateral sclerosis | |
Selective loss of neurofilament proteins after exposure of differentiated human IMR-32 neuroblastoma cells to oxidative stress | |
Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions | |
Serum and cerebrospinal fluid biochemical markers of ALS | |
Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). | |
Simultaneous ALS and SCA2 associated with an intermediate-length <i>ATXN2</i> CAG-repeat expansion | |
Simultaneous and independent detection of C9ORF72 alleles with low and high number of GGGGCC repeats using an optimised protocol of Southern blot hybridisation | |
Small RNA Sequencing of Sporadic Amyotrophic Lateral Sclerosis Cerebrospinal Fluid Reveals Differentially Expressed miRNAs Related to Neural and Glial Activity. | |
SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits | |
Stable transgenic C9orf72 zebrafish model key aspects of the ALS/FTD phenotype and reveal novel pathological features | |
Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey | |
Stiff-man syndrome and its variants | |
Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis | |
Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis | |
Superoxide-induced nitric oxide release from cultured glial cells. | |
Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy | |
Tardbpl splicing rescues motor neuron and axonal development in a mutant tardbp zebrafish | |
TDP-43 induces p53-mediated cell death of cortical progenitors and immature neurons. | |
Telomere length is greater in ALS than in controls: a whole genome sequencing study | |
Thalamic neuronal dysfunction and chronic sensorimotor distal symmetrical polyneuropathy in patients with type 1 diabetes mellitus | |
Thyroid disease and the nervous system | |
TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions | |
Transcriptional response of the neuromuscular system to exercise training and potential implications for ALS | |
Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis. | |
Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS. | |
Type 2 diabetes mellitus-associated transcriptome alterations in cortical neurones and associated neurovascular unit cells in the ageing brain | |
Unravelling the enigma of selective vulnerability in neurodegeneration: motor neurons resistant to degeneration in ALS show distinct gene expression characteristics and decreased susceptibility to excitotoxicity | |
Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis | |
Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer's Disease | |
Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials | |
Use of non-invasive ventilation at end of life | |
Using technology to improve access to specialist care in amyotrophic lateral sclerosis: A systematic review | |
Using telehealth in motor neuron disease to increase access to specialist multidisciplinary care: a UK-based pilot and feasibility study | |
Using transcutaneous carbon dioxide monitor (TOSCA 500) to detect respiratory failure in patients with amyotrophic lateral sclerosis: A validation study | |
Validation of quality of life instruments in ALS. | |
Validation of the historical adulthood physical activity questionnaire (HAPAQ) against objective measurements of physical activity | |
Vascular endothelial growth factor counteracts the loss of phospho-Akt preceding motor neurone degeneration in amyotrophic lateral sclerosis | |
Viral delivery of antioxidant genes as a therapeutic strategy in experimental models of amyotrophic lateral sclerosis | |
Viral delivery of C9orf72 hexanucleotide repeat expansions in mice leads to repeat-length-dependent neuropathology and behavioural deficits | |
White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. | |
The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype | |
Wild-type but not mutant SOD1 transgenic astrocytes promote the efficient generation of motor neuron progenitors from mouse embryonic stem cells | |
Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias | |
ZNStress: a high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis | |
মুখবন্ধ |